Evaluation of New HIV Testing Technologies in Clinical Settings with High HIV Incidence

Funding Agency:
Centers for Disease Control and Prevention

The purpose of this Notice of Funding Opportunity (NOFO) is to develop and implement protocols and recruitment strategies to evaluate the performance (sensitivity and specificity) of HIV tests under development, and/or newly available HIV tests, for use in point-of-care settings in the United States using fresh (unprocessed) specimens such as whole blood and oral fluid. Test sensitivity early in infection, when the antibody response is developing, and during conditions that might affect the detection of an analyte (HIV RNA, antigenic protein or antibody), is of particular interest; for example, determining test sensitivity in patients taking medications for antiretroviral therapy (ART) or HIV pre-exposure prophylaxis (PrEP). Therefore, protocols should address strategies for recruitment of patients with early HIV infection before they initiate ART, patients with HIV infection using ART, and HIV negative patients taking PrEP.

Only one application per institution is allowed


  • Duke Internal: Interested applicants should contact Paul Noe (paul.noe@duke.edu) as early as possible.
  • Letter of Intent: Mar. 16, 2020
  • Application: Apr. 14, 2020




Medical - Basic Science
Medical - Clinical Science

External Deadline

April 14, 2020